

# DASS App User Guide

28 December, 2021

## Contents

<b>About</b>	<b>1</b>
<b>System Requirements</b>	<b>2</b>
<b>Data Import</b>	<b>2</b>
<b>Step 1: Select Defined Approaches</b>	<b>2</b>
2 out of 3 . . . . .	2
Integrated Testing Strategy . . . . .	2
Key Event 3/1 Sequential Testing Strategy . . . . .	3
<b>Step 2: Select Data Columns for Predictions</b>	<b>3</b>
DPRA . . . . .	4
h-CLAT . . . . .	4
KeratinoSens™ Call . . . . .	4
OECD QSAR Toolbox . . . . .	4
<b>Step 3: Review Selection</b>	<b>5</b>
<b>Step 4: Results</b>	<b>5</b>
<b>References</b>	<b>5</b>

## About

This app uses the Defined Approaches for Skin Sensitization (DASS) outlined in the OECD DASS Guideline No. 497. The Defined Approaches (DAs) integrate results from *in vitro* and *in silico* test methods to predict chemical hazard potential.

To launch the app, click the run\_app.bat file.

## System Requirements

This app works on Windows. This app requires R. When first launching the app locally, the *renv*[1] package will be installed. While launching, the *data.table*[2], *DT*[3], *shiny*[4], *shinyBS*[5], and *shinyjs*[6] packages will be installed.

This app was created using R v.4.1.2[7] and has been tested in Google Chrome v.91 on Windows 10.

## Data Import

To begin, click *Browse* to upload your data. The data file must be comma-delimited (.csv) or tab-delimited (.tsv, .txt). The first row should contain column names. Columns must be formatted as described in Step 2. Once you select a file, the data can be viewed by clicking on the *Data* tab.

## Step 1: Select Defined Approaches

After uploading your data, the *Step 1* tab will open. Select the DAs you want to apply and click Done. The DAs are based on the first 3 key events (KEs) in the Adverse Outcome Pathway (AOP) for Skin Sensitization Initiated by Covalent Binding to Proteins[8].

The KEs are covered by validated OECD test methods:

1. The direct peptide reactivity assay (DPRA)[9] maps to the first KE, protein binding.
2. The KeratinoSens<sup>TM</sup>[10] assay maps to the second KE, keratinocyte activation.
3. The human cell line activation test (h-CLAT)[11] maps to the third KE, dendritic cell activation.

### 2 out of 3

The 2 out of 3 (2o3) DA is a sequential testing strategy that identifies skin sensitization hazard based on KEs 1-3. Two concordant results from DPRA, KeratinoSens<sup>TM</sup>, or h-CLAT determine the final classification as a sensitizer or non-sensitizer. If there are only results from two assays and the results are discordant, the chemical can't be classified and will return an "Inconclusive" result.

2o3 does not evaluate potency.

## Integrated Testing Strategy

This app implements version 2 of the Integrated Testing Strategy (ITSv2) DA. ITSv2 predicts skin sensitization hazard potential and potency category based on KEs 1 and 3 and *in silico* predictions from the OECD QSAR Toolbox[12]. Chemicals are scored for each assay result and the summed scores are used to predict chemical hazard and potency using the scoring schemes in Tables 1 and 2.

Score	h-CLAT MIT ( $\mu\text{g/mL}$ )	DPRA mean Cysteine and Lysine % depletion	DPRA Cysteine % depletion	OECD QSAR Toolbox
3	$\leq 10$	$\geq 42.47$	$\geq 98.24$	
2	$> 10, \leq 150$	$\geq 22.62, < 42.47$	$\geq 23.09, < 98.24$	
1	$> 150, \leq 5000$	$\geq 6.38, < 22.62$	$\geq 13.89, < 23.09$	Positive
0	Negative (Not calculated)	$< 6.38$	$< 13.89$	Negative

Table 1. Test method scoring scheme for version 2 of the Integrated Testing Strategy defined approach, adapted from [13]

Combined Score	DPRA + h-CLAT + OECD QSAR TB	DPRA + h-CLAT	DPRA + OECD QSAR TB or h-CLAT + OECD QSAR TB
7	UN GHS 1A	-	-
6	UN GHS 1A	UN GHS 1A	-
5	UN GHS 1B	UN GHS 1*	-
4	UN GHS 1B	UN GHS 1B	UN GHS 1*
3	UN GHS 1B	UN GHS 1B	UN GHS 1*
2	UN GHS 1B	UN GHS 1B	UN GHS 1B
1	NC	Inconclusive	Inconclusive
0	NC	NC	Inconclusive

Table 2. Potency predictions for combined scores from available information sources. 1\* indicates conclusive for hazard, inconclusive for potency. Adapted from [13].

## Key Event 3/1 Sequential Testing Strategy

The KE 3/1 Sequential Testing Strategy (STS) predicts skin sensitization hazard and potency based on KEs 1 and 3. If the h-CLAT predicts a sensitizer, then the potency category is determined by the h-CLAT Minimum Induction Threshold (MIT). If the h-CLAT predicts a non-sensitizer, then the DPRA result defines both hazard and potency. The KE 3/1 STS scheme is shown in Table 3.

Test Method	Result	Hazard	Potency
h-CLAT	MIT $\leq 10$	Positive	1A
h-CLAT	MIT $> 10, < 5000$	Positive	1B
h-CLAT	MIT Negative	Use DPRA	Use DPRA
DPRA	Positive	Positive	1B
DPRA	Negative	Negative	NC

Table 3. Hazard and potency prediction scheme. Adapted from [14] and [15]

## Step 2: Select Data Columns for Predictions

After clicking “Done,” the panel for column selection will expand. All endpoints needed to apply the selected DAs will be shown. Use the dropdown menus to select the columns corresponding to the given assay result. Click “Done” to evaluate the values in the column for proper formatting.

Columns must be formatted correctly to ensure an accurate prediction. A description of the column requirements are given below.

## **DPRA**

### **% Depletion**

DPRA % Depletion is used in ITSv2. The % Cysteine and % Lysine depletion columns must contain only numbers or NA if there is no DPRA outcome for the given chemical. Negative values imply co-elution. If the value for Cysteine is negative, then % Depletion can't be used to predict skin sensitization. If only the value for Lysine is negative, then % Cysteine depletion can be used for scoring (Table 1). Otherwise, the mean of % Cysteine depletion and % Lysine depletion will be used to score the chemical.

### **Call**

DPRA call should be an indicator for a positive or negative outcome from DPRA. Positive outcomes must be indicated by “p,” “pos,” “positive,” or 1. Negative outcomes must be indicated by “n,” “neg,” “negative,” or 0. Any other values will not be used to predict skin sensitization hazard.

If % Cysteine depletion and % Lysine depletion are required, you will have the option to use those values to derive the positive or negative calls. Calls are defined as outlined in OECD Test Guideline 442c [9].

## **h-CLAT**

### **Call**

h-CLAT call should be an indicator for a positive or negative outcome from h-CLAT. Positive outcomes must be indicated by “p,” “pos,” “positive,” or 1. Negative outcomes must be indicated by “n,” “neg,” “negative,” or 0. Any other values will not be used to predict skin sensitization hazard.

### **Minimum Induction Threshold**

h-CLAT minimum induction threshold (MIT) must contain either positive numeric values for positive outcomes or “n,” “neg,” “negative,” or “Inf” to indicate a negative outcome. Any other values will not be used to predict skin sensitization potency. Missing values will not be used to predict skin sensitization potency.

## **KeratinoSens™ Call**

KeratinoSens™ call should be an indicator for a positive or negative outcome from the KS assay. Positive outcomes must be indicated by “p,” “pos,” “positive,” or 1. Negative outcomes must be indicated by “n,” “neg,” “negative,” or 0. Any other values will not be used to predict skin sensitization hazard.

## **OECD QSAR Toolbox**

### **Call**

The OECD QSAR Toolbox (TB) call should be an indicator for a positive or negative prediction where positive predictions are indicated by “p,” “pos,” “positive,” or 1. Negative predictions must be indicated by “n,” “neg,” “negative,” or 0. Any other values will not be used to predict skin sensitization hazard.

## Applicability Domain

The OECD QSAR Toolbox (TB) applicability domain (AD) should be an indicator for whether the chemical is in the AD of the toolbox’s models. A value of “In” or 1 indicates that the chemical is in the AD. A value of “Out” or 0 indicates that the chemical is outside the AD and the OECD QSAR TB prediction will not be used to predict skin sensitization potency.

## Step 3: Review Selection

The selected columns will be evaluated for proper formatting. In the *Step 3* tab, a table with the selected columns will show if any columns contain invalid values. Click “Run” to run the DASS predictions. If flagged columns were not fixed prior to running the predictions, any invalid values will be marked as missing and will not be used to predict skin sensitization hazard and potency.

## Step 4: Results

The *Step 4* tab will show a table with the original data with the DASS prediction columns appended to the end. The table will also contain new columns with the converted column values that were used in the predictions. This may be useful if predictions were run on flagged data.

Click the *Download Results* button to download an excel sheet with the results table.

## References

1. Ushey K. Renv: Project environments. 2021. Available: <https://CRAN.R-project.org/package=renv>
2. Dowle M, Srinivasan A. Data.table: Extension of ‘data.frame’. 2021. Available: <https://CRAN.R-project.org/package=data.table>
3. Xie Y, Cheng J, Tan X. DT: A wrapper of the JavaScript library ‘DataTables’. 2021. Available: <https://CRAN.R-project.org/package=DT>
4. Chang W, Cheng J, Allaire J, Sievert C, Schloerke B, Xie Y, et al. Shiny: Web application framework for r. 2021. Available: <https://CRAN.R-project.org/package=shiny>
5. Bailey E. shinyBS: Twitter bootstrap components for shiny. 2015. Available: <https://CRAN.R-project.org/package=shinyBS>
6. Attali D. Shinyjs: Easily improve the user experience of your shiny apps in seconds. 2020. Available: <https://CRAN.R-project.org/package=shinyjs>
7. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2021. Available: <https://www.R-project.org/>
8. OECD. The adverse outcome pathway for skin sensitisation initiated by covalent binding to proteins. 2014. p. 105. doi:<https://doi.org/https://doi.org/10.1787/9789264221444-en>
9. OECD. Test no. 442C: In chemico skin sensitisation. 2021. p. 40. doi:<https://doi.org/https://doi.org/10.1787/9789264229709-en>
10. OECD. Test no. 442D: In vitro skin sensitisation. 2018. p. 51. doi:<https://doi.org/https://doi.org/10.1787/9789264229822-en>
11. OECD. Test no. 442E: In vitro skin sensitisation. 2018. p. 65. doi:<https://doi.org/https://doi.org/10.1787/9789264264359-en>

12. Yordanova D, Schultz TW, Kuseva C, Tankova K, Ivanova H, Dermen I, et al. Automated and standardized workflows in the OECD QSAR toolbox. *Computational Toxicology*. 2019;10: 89–104. doi:<https://doi.org/10.1016/j.comtox.2019.01.006>
13. OECD. Guideline no. 497: Defined approaches on skin sensitisation. 2021. p. 54. doi:<https://doi.org/https://doi.org/10.1787/b92879a4-en>
14. Nukada Y, Miyazawa M, Kazutoshi S, Sakaguchi H, Nishiyama N. Data integration of non-animal tests for the development of a test battery to predict the skin sensitizing potential and potency of chemicals. *Toxicology in Vitro*. 2013;27: 609–618. doi:<https://doi.org/10.1016/j.tiv.2012.11.006>
15. Takenouchi O, Fukui S, Okamoto K, Kurotani S, Imai N, Fujishiro M, et al. Test battery with the human cell line activation test, direct peptide reactivity assay and DEREK based on a 139 chemical data set for predicting skin sensitizing potential and potency of chemicals. *Journal of Applied Toxicology*. 2015;735: 1318–1332. doi:<https://doi.org/10.1002/jat.3127>